Real World Use of Pegylated Erythropoietin in CKD Anemia: An Indian Modified Delphi Consensus

Abstract excerpt

<title>Abstract</title> <p>Background Anemia is a common complication in chronic kidney disease (CKD) and is associated with adverse outcomes particularly in the advanced stage. Iron therapy and Erythropoesis stimulating agents (ESAs) form the cornerstone of its management. Among ESAs, there are various options available for usage, however each one differs in its structure and frequency of administration. Pegyla...

Topics

Open a Topic to create a Post that cites this publication.

• Anemia
• Cancer, Hypoxia, and Metabolism
• Erythropoietin and Anemia Treatment
• Iron Metabolism and Disorders
• Phenotype
• Quality of Life
• Renal Dialysis
• Renal Insufficiency, Chronic

Identifiers and source

Literature Corpus work

296fb779-bbb6-5775-86ff-7765fa0cf93f

DOI

10.21203/rs.3.rs-8706096/v1